Syndax Pharmaceuticals, Inc. (SNDX)

NASDAQ • Healthcare

$13.4

-$0.16 (-1.3%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$13.6

Previous Close$13.4

Day Range$13.2 - $13.61

Avg. Volume (3M)2.4M

Market Cap$1.1B

52 Week Range

$12.8$25.59

Next EarningsIn 8 daysNov 2, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$72.7M100%

Gross Profitminus cost of goods$69.5M96%

In plain terms: out of every $100 in revenue, Syndax Pharmaceuticals, Inc. currently loses $68.

Fundamentals & Financials

Revenue (TTM)

$252M

Net Income (TTM)

-$220.7M

EPS (TTM)

-$2.52

ROA (TTM)

-31.37%

Current Ratio

6.77

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+17.0%Q3 2025-$0.83

+5.4%Q4 2025-$0.7

-33.6%Q1 2026-$0.78

+18.6%Q2 2026-$0.48

-22.9%Q3 2026-$0.55

Nov 2

in 8 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -22.9%

Syndax Pharmaceuticals’ results for the second fiscal quarter of 2026 missed consensus on both EPS and revenue, as reported August 4, 2026, even as revenue surged year over year. Revenue rose 91.8% to about $72.8 million (up from $38.0 million a year ago) but trailed expectations, with revenue of $72.8 million versus the $79.4 million estimate (-8.3%). EPS of -$0.55 also trailed the -$0.45 estimate by -$0.10, though it improved from -$0.83 a year ago (+33.7% YoY). Profitability remained shaped by operating spend, with gross profit of roughly $69.6 million translating to a gross margin of ~96%, while operating income was -about $40.0 million and operating margin was -55%. Net income was -about $49.4 million, improving 31.3% from -$71.8 million in the year-ago quarter. Cash use continued, with negative operating cash flow of about $30.3 million. For the next period, consensus calls for EPS of -$0.48 on revenue of $81.9 million.

Next report — what to expect

Syndax Pharmaceuticals, Inc. (SNDX) reports earnings on November 2, 2026. Wall Street is looking for EPS of -$0.479 on revenue of $82.4 million. For trailing context, revenue grew +91.8% year over year last quarter. SNDX has beaten EPS in 5 of 8 most recent quarters, a key point to watch versus consensus.

View full earnings history

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company developing cancer therapies, with a clinical-stage pipeline centered on targeted and immune-mediated treatments. In FY2025, it generated $172.4 million in revenue. Its main programs are SNDX-5613 for certain acute leukemias, SNDX-6352 for chronic graft versus host disease, and entinostat.

Name

Syndax Pharmaceuticals, Inc.

CEO

Michael A. Metzger

Website

www.syndax.com

Industry

Healthcare

Year Founded

2005

Employees

298

Today's Snapshot

AI-generated

SNDX closed 1.2% below yesterday's close, in line with a weaker sector. The day ended with SNDX within 4.7% of its 52-week low of 12.79.

Trading Volume

Above 10d avg 3.3M

4.1M

vs S&P 500 Today

Underperforming Market

-0.73%

Updated: October 23, 2026 at 20:13 UTC

Technical Indicators

2 Buy0 Neutral6 Sell

SNDX is technically dominated by a pronounced downtrend, with ADX well above 40 signaling strong directional momentum while price remains beneath all major averages including the 200-day. Momentum indicators and MACD are negative and on-balance volume shows heavy outflows, though several oscillators register oversold readings. Volatility is material with ATR around 5.8%, so moves can be sharp, and short-term stochastic and RSI suggest oversold conditions rather than strength. The classic pivot sits at the current level but has not reversed the trend. Technical takeaway: Strong sell condition driven by a robust downtrend, selling volume, and persistent weakness.

All signals